Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis. EydisBio is an...
oral testosterone treatment for men. Together, they aim to conduct a pioneering study that will measure the impact of GLP-1s on muscle mass in male patients using the treatment for weight loss. In conjunction with muscle mass reduction being a...
and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial...
due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and...
market and beyond. This acquisition enables MECOTEC to manufacture and supply Restore's signature cryo-chamber models—the 1Cool, 2Cool, and 4Cool—exclusively to Restore locations in the United States, while also offering these designs to MECOTEC's...
At Fakuma, Netstal will be producing 10 ml syringe barrels with Luer-Lock adapters made of COC using an all-electric Elion MED with a clamping force of 1750 kN.The part weight is 7.8 g and the cycle time is around 20 seconds. Netstal processes a...
many rare and genetic kidney diseases including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS) and APOL1-mediated kidney disease (AMKD). Members connect with each other to learn about policy issues impacting kidney care, receive...
Since the residence time of the drug particles in the stomach (~2-3 hours) is much shorter than the usual dosing interval (~12-24 hours), the blood concentration of such drugs fluctuates significantly with repeated intake. This is not...
C. Mary, MD, Founder and Medical Director of The Remedy Room in New Orleans said, “We have utilized NAD IV therapy for 11 years and are excited to introduce Niagen IV in partnership with ChromaDex, a cutting-edge advancement. With Niagen IV, our...
range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality...
pharmaceutical company developing proprietary cannabinoid therapeutics, announced that the first patient has received BRC-001, an experimental supportive care therapy for breast cancer patients. City of Hope researchers are evaluating whether this...
raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue of RMB 2.811 billion (~ USD 393.54 million) for the first half of the year, with a net profit of RMB 342 million (~ USD 47.88 million)...
and courier for potential self-administration. The clinical study includes 258 healthy participants between the ages of 18 and 50 years, making it the largest Phase I trial conducted-to-date by Vaxxas with its HD-MAP technology. The trial will...
chemotherapy for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on ≥50% of tumor cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for...
(FDA) will hold an advisory committee meeting with the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on October 10, 2024 to evaluate the New Drug Application (NDA) for elamipretide, the first potential therapy for Barth syndrome. This...
homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify® Digital Pathology platform. This marks...
company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist. Aisa is developing AISA-021 for the treatment of Systemic Sclerosis...
studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. About Genprex, Inc.: Genprex, Inc. is a clinical-stage gene therapy company focused on...
Guidelines as an ancillary tool in the diagnosis and monitoring of UTUC. Bladder cancer is the sixth most common cancer[1] as there are approximately 760,000 people in Europe living with the disease[2]. Surveillance is of paramount importance for...